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Breast tumor characteristics of BRCA1
and BRCA2 gene mutation carriers on MRI
Abstract The appearance of malig-
nant lesions in BRCA1 and BRCA2
mutation carriers (BRCA-MCs) on
mammography and magnetic reso-
nance imaging (MRI) was evaluated.
Thus, 29 BRCA-MCs with breast
cancer were retrospectively evaluated
and the results compared with an age,
tumor size and tumor type matched
control group of 29 sporadic breast
cancer cases. Detection rates on both
modalities were evaluated. Tumors
were analyzed on morphology, density
(mammography), enhancement pat-
tern and kinetics (MRI). Overall
detection was significantly better with
MRI than with mammography (55/58
vs 44/57, P=0.021). On mammogra-
phy, lesions in the BRCA-MC group
were significantly more described as
rounded (12//19 vs 3/13, P=0.036)
and with sharp margins (9/19 vs 1/13,
P=0.024). On MRI lesions in the
BRCA-MC group were significantly
more described as rounded (16/27 vs
7/28, P=0.010), with sharp margins
(20/27 vs7/28, P<0.001) andwith rim
enhancement (7/27 vs 1/28, P=0.025).
No significant difference was found
for enhancement kinetics (P=0.667).
Malignant lesions in BRCA-MC fre-
quently have morphological charac-
teristics commonly seen in benign
lesions, like a rounded shape or sharp
margins. This applies for both mam-
mography and MRI. However the
possibility of MRI to evaluate the
enhancement pattern and kinetics
enables the detection of characteristics
suggestive for a malignancy.
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Introduction
BRCA1 and BRCA2 are the most well known gene
mutations responsible for an increased risk for developing
breast cancer. A BRCA1 or BRCA2 mutation carrier
(BRCA-MC) has approximately a 3% risk of getting breast
cancer before the age of 30. This risk increases to almost
50% when she reaches the age of 50 and becomes 50–80%
at the age of 70 [1, 2]. To reduce this risk, these women can
choose between bilateral prophylactic mastectomy [3],
oophorectomy [4] or chemoprevention [5]. In breast
cancer, close surveillance contributes to a more favorable
stage of disease at detection and may reduce the rate of
death from breast cancer [6, 7].
In the surveillance or general screening for breast cancer,
mammography still plays a prominent role. However, due
to the young age and thus in most cases dense breast tissue,
the sensitivity for mammography is moderate. False-
negative rates of up to 62% have been reported for
mammography in screening gene mutation carriers [8, 9].
A malignant lesion in the breast is mammographically best
detected if it presents itself as an ill-defined or spiculated
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distortion. A smoothly outlined well-defined mass detected
on mammography has a chance of less than 1% of being
malignant [10, 11]. Tilanus et al. [12] and Kaas et al. [13,
14] have evaluated the mammographic appearance of
breast cancer in BRCA-MC. Tilanus and coworkers found
the mammographic appearance suspicious for a malignan-
cy in only 38% of the gene carriers in comparison with
71% in a control group. “Prominent pushing margins”
caused by a continuous front of tumor cells not separated
by connective tissue were described in the BRCA-MC
group as the main reason for a false-negative evaluation of
mammograms [12]. Kaas and coworkers concluded in their
study of 31 breast cancer cases in BRCA-MCs that all
mammographically detected lesions should be further
evaluated by ultrasound and biopsy regardless of their
appearance [13]. Well-defined mammographic tumors
correlated in 83% with histologic circumscribed tumor
margins in BRCA1-MCs [14].
For women with an increased risk for developing breast
cancer magnetic resonance imaging (MRI) should be
included for close surveillance [15, 16]. The superior
sensitivity of MRI (81%) for the detection of breast cancer
in these women compared with mammography (40%) has
been proven in literature [17]. However the classification
of a lesion detected on MR as benign or malignant still
remains a challenge. Morphological and dynamic features
are important in breast MRI interpretation. Focal masses
with smooth borders are associated with a high negative
predictive value for malignancy [17]. An irregular lesion
contour, inhomogeneous enhancement pattern and rim
enhancement have been reported as features indicating
malignancy [18]. The dynamic evaluation is often based on
the enhancement characteristics 2–7 min after the injection
of a paramagnetic contrast agent. In this approach, the
decrease of signal intensity, often referred to as a type 3
curve or washout, is highly predictive for breast cancer,
with a likelihood of malignancy of 87% [19]. Until now the
appearance of breast malignancies in BRCA-MCs has only
been investigated for mammography. In this study we
analyzed the MRI characteristics of BRCA-MC-associated
tumors compared with sporadic cases of breast cancer.
Materials and methods
All available (35) BRCA-MCs with a biopsy-proven
malignancy, imaged with MRI for screening [9] or pre-
operative evaluation in the period from July 2000 until
November 2006, were included in the study: 23 BRCA1
carriers and 12 BRCA2 carriers. In order to compare tumor
characteristics with sporadic cases of breast cancer an age,
tumor type and tumor size matched control group was
composed from 206 consecutive sporadic breast cancer
cases imaged with MRI in the period from November 2001
until January 2007. All BRCA-MC cases were age
matched within 5 years with sporadic breast cancer cases.
Cases were also matched for tumor type (IDC, ILC or
DCIS) and pathological tumor size. For size matching, the
BRCA-MC cases were matched to the closest tumor size in
the sporadic cases available, with a limit for the maximum
size difference of 0.5 cm for tumors smaller than 1 cm, 1-cm
difference for tumors up to 5 cm and 1.5-cm difference for
tumors larger than 5 cm. BRCA-MC cases that could not be
matched following these criteria were excluded.
Mammograms were obtained in the mediolateral
oblique and craniocaudal direction on a digital mammog-
raphic unit (Senograph 2000 D or a Senograph DS, GE
Healthcare, Wis., USA). Detection, density of the lesion
compared with breast tissue, lesion morphology, and size
were scored. In the morphologic assessment, lesion type
was classified as either a mass, a calcifications or as an
architectural distortion. Lesion shape was described as
rounded, lobulated or irregular and lesion margins as
sharp, vague or spiculated. The size of the tumor was
measured by determining the longest axis through the
displayed lesion. Spiculae surrounding a solid lesion were
interpreted as desmoplastic reaction and not included in
the measurement.
MRI investigations were performed on a 1.5-Tesla
system with a double breast coil (Magnetom Vision,
Sonata or Symphony, Siemens, Erlangen, Germany). In the
scanning, we used a coronally orientated three-dimensional
fast low-angle shot (FLASH 3D) with the following
parameters: TE 4 ms, TR 8.1 ms, FA 20°, FOV 360 mm,
TA 96 s, image resolution 1.5 mm×1.5 mm×1.5 mm for all
patients scanned prior to June 2004 and TE 4 ms, TR
7.5 ms, FA 8°, FOV 320 mm, TA 87 s, image resolution
1.3 mm×1.3 mm×1.3 mm for all patients scanned after
June 2004.
Prior to the MR examination, an intravenous catheter
was inserted. All patients were placed in the prone position,
with the breasts in the double breast coil and positioned at
the isocenter of the magnet. After localizer images were
obtained in three directions and a precontrast FLASH 3D
series was recorded, 0.1 mmol/kg bodyweight gadolinium
chelate (Magnevist, Schering, Germany or Dotarem,
Guerbet, The Netherlands) was administered using a
power injector (Spectris, Medrad, USA) at 2.5 ml/s
followed by a 15-ml saline flush at the same injection
rate. Thereafter, five post contrast FLASH 3D series were
recorded.
All MRI examinations were retrospectively evaluated on
a dedicated breast MRI workstation (Dynacad, Invivo,
USA) scoring lesion detection, size, morphology and
enhancement kinetics. Maximum intensity projections,
coronal images and axial reconstructions of both the T1
weighted and subtracted images and time-intensity curves
were displayed. The morphologic assessment included
lesion shape, margin appearance and enhancement pattern.
Lesion shape was classified as being rounded, lobulated or
irregular. Margins were described as sharp, vague or
932spiculated. The enhancement pattern of a lesion was
classified as homogeneous, heterogeneous or rim en-
hanced. Lesion enhancement kinetics were evaluated
according to the criteria described by Kuhl et al. [19].
Type 1 shows persistent enhancement and is highly
suggestive for a benign lesion. Type 2 shows a plateau
after initial increased enhancement, where the maximum
signal intensity is reached approximately 2–3 min after
contrast injection and remains constant. This type of curve
is seen in both benign and malignant lesions. In a type 3
curve, the peak enhancement is reached in the early
postcontrast phase, and this is followed by a decrease of
signal intensity (wash-out). The latter curve is strongly
suggestive for a malignant lesion. The dynamic curves
were evaluated based on a single voxel or by selecting a
region of interest within the lesion, the workstation allowed
the readers to use both methods. Because of the possible
bias in this retrospective study, a BI-RADS classification
[20] could not be scored objectively and was therefore not
included in the evaluation.
All studies were evaluated retrospectively by two
radiologists in conference and consensus. BRCA-MCs
and controls were mixed during the evaluation. Except
from the knowledge of a malignancy being present, the
radiologists were blinded to any other clinical information.
Mammography and MRI images were evaluated in sepa-
rate sessions. From the histopathology reports, the tumor
type, size and mitotic activity index (MAI) were recorded.
The study was approved by the institutional review board;
since the study was performed retrospectively, informed
consent was not required according to the review board.
In the statistical evaluation, differences in patient and
tumor characteristics between the BRCA-MC and control
group were analyzed using an independent sample t-test if
variables were continuous and normally distributed. For
categorical variables, the Pearson chi-square test was used
and we used Fisher’s exact test when any of the expected
values was less than five. Pearson’s correlation coefficients
were calculated for both mammographic size and MRI size
versus pathologic size. All statistical analyses were
performed using SPSS statistical software (version
12.0.1). P values<0.05 were considered to indicate
statistical significance.
Results
Six BRCA-MC cases could not be matched according to
the criteria defined; these cases were excluded from the
study. Four BRCA-MCs were excluded because no match
could be found based on patient’s age; the other two were
excluded because no match could be found based on tumor
size.
The mean age and tumor size of the excluded cases were,
respectively, 33 years (range 27–36, median 35, SD
3.4 years) and 1.4 cm (range 0.6–2.8 cm, median 1.1 cm,
SD 0.8 cm). A total of 29 BRCA-MC cases were included
for this study. In the BRCA-MC group, five women were
symptomatic (17%); 21 women were symptomatic in the
control group (83%).
Mean age in the BRCA-MC group was 42 years (range
32–68 years, median 40 years, SD 8.0 years); this was 44
(range 37–64 years, median 43 years, SD 5.6 years) for the
control group. The mean pathological tumor size was
2.0 cm (range 0.4–7.0 cm, median 1.4 cm, SD 1.5 cm) in
the BRCA-MC group and 2.3 cm (range 0.6–7.0 cm,
median 1.9 cm, SD 1.7 cm) in the control group. No
significant difference was found for patient age (P=0.289)
or maximal pathological tumor size (P=0.371).
The mean tumor size on mammography was 2.1 cm
(range 0.5–7.0 cm, median 1.5 cm, SD 1.49 cm). The mean
tumor size on MRI was 2.4 cm (range 0.6–7.1 cm, median
1.8 cm, SD 1.75 cm).
There was a significant correlation between imaging
measurements and pathological measurements; 0.664 (P<
0.001) for mammographic measurements and 0.808 (P<
0.001) for MRI measurements.
In both the BRCA-MC and control groups, 23 cases
were based on invasive ductal carcinoma (IDC), two cases
on invasive lobular carcinoma (ILC), one case on ductal
carcinoma in situ grade 1 (DCIS1) and three cases on
ductal carcinoma in situ grade 2 (DCIS2). In the BRCA-
MC group, a mean MAI of 33.0 (range 6–100, median 27,
SD 27.1) was found, compared with 17.5 (range 1–60,
median 14, SD 15.9) in the control group. The difference in
MAI between the BRCA-MC and control groups was
found to be significant (P=0.044).
In the control group, one patient refused to undergo
mammography because of implants. Overall mammogra-
phy detected 44 of 57 lesions and MRI detected 55 of 58
lesions. Therefore, the overall detection is significantly
better with MRI than with mammography (P=0.021).
Mammography detected 22 (76%) lesions in the BRCA-
MC group and 22 (79%) in the control group. No
significant difference was found (P=0.807). All lesions
missed on mammography in the BRCA-MC were IDC. In
the control group, five cases of IDC and one case of ILC
were missed. Mammographic lesion characteristics are
presented in Table 1. Lesions in the BRCA-MC group were
significantly more described as rounded (12//19 vs 3/13,
P=0.036) and were more often described to have sharp
margins (9/19 vs 1/13, P=0.024). Lesions in the control
group were significantly more described as irregular (10/13
vs 6/19, P=0.029). From the six BRCA-MCs that were
excluded, only three lesions were detected on mammog-
raphy. In two cases a mass was detected and in one case
calcifications. Both these masses were described as
rounded with sharp margins.
On MRI, 27 lesions (93%) were detected in the BRCA-
MC group, 28 (97%) in the control group. No significant
difference was found (P=0.553). The lesions missed in the
BRCA-MC group were both cases of DCIS, one case of
933DCIS1, seen on mammography as an architectural distor-
tion, and one case on DCIS2, seen on mammography as a
mass. The lesion missed in the control group was based on
DCIS2, seen on mammography as calcifications. Their was
no significant difference found for the detection of breast
cancer between mammography and MRI within the
BRCA-MC (P=0.18) or the control group (P=0.13).
Morphological and dynamic MR characteristics are pre-
sented in Table 2. Lesions in the BRCA-MC group were
significantly more often described as rounded (16/27 vs
7/28, P=0.010), with sharp margins (20/27 vs 7/28, P<
0.001) and to show rim enhancement (7/27 vs 1/28, P=
0.025). Lesions in the control group were significantly
more often described as irregular (18/28 vs 8/27, P=0.010),
with vague margins (15/28 vs 6/27, P=0.017) and with a
heterogeneous enhancement pattern (22/28 vs 12/27, P=
0.009). No significant difference between the two groups
was found for enhancement kinetics (P=0.667). From the
six BRCA-MCs that were excluded, five were detected on
MRI. Four of these lesions were described as rounded, one
as irregular. The delineation was described as sharp in four
and as vague in one of these cases. The enhancement
pattern was described as homogeneous in two, heteroge-
neous in one and as rim-enhancement in two of these cases.
All five cases showed a type 3 curve.
Discussion
In this study, the overall false-negative rate for mammog-
raphy was significantly higher compared with MRI.
Although it is expected that the sensitivity for MRI in
both the control group and the BRCA-MC is higher
compared with mammography, no significant difference
was found in this study within the two groups. This is
probably due to the relatively small numbers of cases in
this study. Kaas et al. [13] described in their mammogra-
phic study on BRCA1 and BRCA2 mutation carriers a
Table 1 Mammographic lesion
characteristics for both groups
aLesion density, morphology
and margins of mass-like
lesions only
BRCA-MC group Control group P value
Lesions detected n=22 n=22
Lesion type Mass 19 13 0.042
Arch. distortion 1 4 0.345
Calcification 2 5 0.216
Lesion density
a Hyperdense 8 1 0.050
Isodense 11 12 0.050
Lesion morphology
a Rounded 12 3 0.036
Lobulated 1 – 1.000
Irregular 6 10 0.029
Lesion margins
a Sharp 9 1 0.024
Vague 8 8 0.473
Spiculated 2 4 0.194
Table 2 MRI lesion characteris-
tics for both groups
BRCA-MC group Control group P value
Lesions detected n=27 n=28
Lesion morphology Rounded 16 7 0.010
Lobulated 3 3 1.000
Irregular 8 18 0.010
Lesion margins Sharp 20 7 <0.001
Vague 6 15 0.017
Spiculated 1 6 0.049
Enhancement pattern Homogeneous 8 5 0.304
Heterogeneous 12 22 0.009
Rim 7 1 0.025
Enhancement kinetics Type 1 1 2 1.000
Type 2 4 6 0.525
Type 3 22 20 0.380
934sensitivity of 64% for the detection of a tumor in the
original reports. In this study, 76% of the lesions were
visible on mammography. Since this was a retrospective
study and the radiologist was aware of the fact that a tumor
was present at the time of the evaluation, no conclusion can
be drawn from the difference in detection between both
studies.
On mammography, the mass like lesions detected in the
BRCA-MC group were significantly more often described
as rounded. Also, lesions were found to differ in margin
appearance; tumor margins in the BRCA-MC group were
significantly more often described as sharp. A smooth,
nonspiculated mass has previously been described by
Tilanus et al. [12] as a reason for a false-negative
mammographic evaluation in BRCA-MC. Thus, although
Sickles et al. [21] described that nonpalpable, circum-
scribed, noncalcified breast masses (probably benign)
should be managed with periodic mammographic surveil-
lance regardless of lesion size and patient age, and
Sardanelli et al. [22] published that both the well-defined
margins and the rounded shape are more often associated
with benign lesions, these findings are not applicable to the
BRCA-MCs studied in this or other studies on this subject.
Tilanus et al. [12] stated that any mammographic mass in
BRCA-MCs must be regarded with suspicion. A similar
conclusion was published by Kaas et al. [13]. An additional
evaluation using ultrasound and biopsy of all lesions
detected in BRCA-MC is mandatory, regardless of their
morphological appearance. In their study of 28 BRCA-
MCs, Hamilton et al. [23] also described the appearance of
breast tumors on ultrasound. On ultrasound, 53% of the
tumors were classified as either benign or indeterminate,
making a biopsy of any detected mass inevitable. We are
also of the opinion that any solid lesion detected in BRCA-
MCs should be evaluated by a biopsy.
In the screening of women with an increased risk for
developing breast cancer, more tumors are detected by
MRI compared with mammography [8, 9]. In this study, all
Fig. 1 a An MLO mammogram
fromtherightbreastofa42-year-
old BRCA1-mutation carrier. b
Acoronal subtraction MR image
of the same breast. An 11-mm
sharply delineated rounded
lesion is present on the mam-
mogram projecting over the
upper quadrants (arrow). On
MRI, the same lesion was
detected (arrow) with rim-
enhancement. The rim-
enhancement makes this lesion
morphologically suspect
malignant. Ultrasound guided
core biopsy proved this lesion to
be an invasive duct carcinoma
Fig. 2 a A coronal subtraction MR image from the right breast of a
49-year-old BRCA1-mutation carrier. Lateral located in the right
breast, a sharply delineated rounded, homogeneous enhancing lesion
is visible with a longest diameter of 9 mm (arrow). b The relative
enhancement versus time curve. The type 3 curve seen for this lesion
was the only characteristic indicating a possible malignancy.
Pathology proved this lesion to be an invasive duct carcinoma
935lesions missed on MRI were cases of DCIS. MRI is known
to have a lower sensitivity in detecting DCIS compared
with invasive carcinomas [24], especially in low-grade
DCIS. The low or intermediate contrast uptake that is often
observed in pure DCIS and the absence of a type 3 curve
can result in a false-negative evaluation [24]. Kriege et al.
[9] found in the screening of 1,909 women with an
increased risk for developing breast cancer, including 358
carriers of germ-line mutations, that MRI missed five cases
of DCIS that were detected on mammography, with six
noninvasive tumors detected in total in the study. However,
Kuhl et al. [25] reported MRI to be more sensitive for DCIS
compared with mammography in a prospective study of
women with an increased risk for developing breast cancer.
AlthoughMRIprovedtobemoresensitiveforthedetection
of DCIS compared with mammography, not all cases of
DCIS were detected by either modality. Therefore, at this
point both modalities are still needed in the screening of
women with an increased risk for developing breast cancer.
Similar to mammography, on MRI a significantly higher
number of lesions were described as rounded and with
sharp margins in the BRCA-MC group. Furthermore, the
number of lesions with ‘rim-enhancement’ was found to be
significantly higher in the BRCA-MC group. The presence
of this enhancement pattern has been associated with
malignant lesions [26, 27]. Because MRI enables the
radiologist to evaluate the enhancement pattern of the
lesion, where mammography does not, these lesions will
become more suspectedly malignant, even though other
morphologic features are more often seen in benign lesions.
The association of rim-enhancement (Fig. 1) with central
necrosis or insufficient microvessel growth can be an
indicator for the growth rate of tumors. Jimenez and
coworkers have described centrally necrotizing carcinomas
to have an accelerated clinical course and early systemic
metastasis [28]. An accelerated growth rate can be
associated with a high MAI. In this study, the MAI was
found to be significantly different between both groups.
This is in agreement with Tilanus et al. [12], who also
found the mitotic count to be significantly higher in tumors
found in gene mutation carriers. The higher rate of sharp
tumor margins and rim-enhancement may thus be ex-
plained by the more aggressive nature of tumors in BRCA-
MCs. Several authors have implied that, due to the rapid
growth rate of tumors in gene mutation carriers, the
screening frequency should be adjusted [13, 29]. Komenaka
et al. [29] suggest a higher screening frequency in carriers
because ofthe high number of intervalcancersfoundintheir
group. Half of these interval malignancies were already
positive for lymph-node involvement. The 13 carriers in
their study were screened with mammography. Mammog-
raphy in carriers is not sensitive, particularly because the
women are young and thus more often have dense breasts
[30, 31]. The use of MRI in screening has already been a
step forward since MRI can detect smaller tumors, often
occult for mammography, that are less likely to have
progressed into lymph-node involvement [9].
Rounded, homogeneous enhancing lesions found on
MRI are in general not considered suspicious. A homoge-
neous enhancement pattern, found in nine BRCA-MCs,
does not contribute to the malignant nature of these lesions.
Therefore, enhancement kinetics are of value. In this study,
the dynamic analysis showed in both the BRCA-MC and
the control groups a type 3 curve in, respectively, 82% and
71% of the cases. As described by Kuhl et al. [19], a type 3
enhancement curve is highly indicative for malignancy.
Using this characteristic, even rounded, sharply delineated,
homogeneous enhancing lesions become suspect malig-
nant (Fig. 2).
Despite all the findings discussed in this study, it remains
questionable if the characterization of a lesion detected on
either mammography or MRI in BRCA-MCs is even
necessary.As the chance for these women to develop breast
cancer is significantly increased, almost any detected lesion
will in practice be classified as suspect malignant until
proven otherwise. Sardanelli et al. [17] found a positive
predictive value for MR in women with an increased risk of
only 53% due to a high number of false positives. As stated
previously for mammographically detected lesions, addi-
tional evaluation by core biopsy is the only definitive
classification for lesions detected in this group of women.
In the case of MRI screening in high risk women, short-
term follow-up, target ultrasound or MRI-guided biopsies
are therefore often indicated [32]. What the best strategy in
this group of women will be, also in terms of cost
effectiveness, needs to be further studied.
We conclude that in BRCA-MC malignant lesions
frequently have morphological characteristics that are
commonly seen in benign lesions, like a rounded mor-
phology or a sharp delineation. This applies for both
mammography and MRI. However, the possibility of MRI
to evaluate the enhancement pattern and enhancement
kinetics of lesions enables the radiologist to detect
characteristics suggestive for a malignancy.
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